Fox Run Management L.L.C. Acquires New Shares in Nektar Therapeutics $NKTR

Fox Run Management L.L.C. acquired a new stake in Nektar Therapeutics (NASDAQ:NKTR) during the 4th quarter, Holdings Channel.com reports. The fund acquired 26,522 shares of the biopharmaceutical company’s stock, valued at approximately $1,121,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. AQR Capital Management LLC lifted its position in Nektar Therapeutics by 336.9% in the 1st quarter. AQR Capital Management LLC now owns 3,640,851 shares of the biopharmaceutical company’s stock valued at $2,463,000 after acquiring an additional 2,807,595 shares in the last quarter. Vanguard Group Inc. lifted its position in Nektar Therapeutics by 30.0% in the 3rd quarter. Vanguard Group Inc. now owns 948,647 shares of the biopharmaceutical company’s stock valued at $53,978,000 after acquiring an additional 219,155 shares in the last quarter. Farallon Capital Management LLC bought a new position in Nektar Therapeutics in the 3rd quarter valued at approximately $45,008,000. Two Seas Capital LP bought a new position in Nektar Therapeutics in the 4th quarter valued at approximately $31,506,000. Finally, Two Sigma Investments LP lifted its position in Nektar Therapeutics by 446.9% in the 3rd quarter. Two Sigma Investments LP now owns 434,237 shares of the biopharmaceutical company’s stock valued at $24,708,000 after acquiring an additional 354,842 shares in the last quarter. 75.88% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. TD Cowen assumed coverage on Nektar Therapeutics in a research report on Tuesday, March 17th. They issued a “buy” rating on the stock. B. Riley Financial reaffirmed a “buy” rating and issued a $150.00 price objective (up from $105.00) on shares of Nektar Therapeutics in a research report on Monday, February 23rd. Jefferies Financial Group reaffirmed a “buy” rating on shares of Nektar Therapeutics in a research report on Wednesday, April 22nd. HC Wainwright upped their price objective on Nektar Therapeutics from $165.00 to $185.00 and gave the company a “buy” rating in a research report on Monday, April 20th. Finally, Citigroup upped their price objective on Nektar Therapeutics from $123.00 to $151.00 and gave the company a “buy” rating in a research report on Tuesday, April 21st. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $149.63.

Nektar Therapeutics Trading Down 0.7%

Shares of NKTR opened at $56.23 on Wednesday. The firm has a market cap of $1.90 billion, a PE ratio of -6.68 and a beta of 1.13. The firm has a fifty day simple moving average of $75.34 and a two-hundred day simple moving average of $62.19. Nektar Therapeutics has a 1-year low of $7.99 and a 1-year high of $109.00.

Nektar Therapeutics (NASDAQ:NKTR) last announced its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.82) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.58) by ($0.24). The company had revenue of $10.86 million for the quarter, compared to analysts’ expectations of $10.69 million. Nektar Therapeutics had a negative net margin of 284.18% and a negative return on equity of 85.40%. As a group, research analysts forecast that Nektar Therapeutics will post -9.45 EPS for the current fiscal year.

Insiders Place Their Bets

In other Nektar Therapeutics news, CEO Howard W. Robin sold 444 shares of the business’s stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $65.51, for a total transaction of $29,086.44. Following the completion of the sale, the chief executive officer directly owned 75,045 shares in the company, valued at approximately $4,916,197.95. The trade was a 0.59% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 2.50% of the company’s stock.

About Nektar Therapeutics

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.